Erica H. Bell

Erica H. Bell's identifiable body of work centers on brain tumors, particularly glioma and glioblastoma, with a focus on molecular markers such as MGMT gene methylation and RRM2 that help predict how patients respond to radiation and chemotherapy. Much of this work involves large multi-center clinical trials (NRG Oncology/RTOG) evaluating combinations of radiation therapy with chemotherapy drugs like temozolomide, nitrosourea, and procarbazine/CCNU/vincristine. Note that the provided publication list also contains records seemingly unrelated to this topic (e.g., nursing communication protocols, whale demography datasets), which may reflect name overlap with other authors rather than this researcher's actual output.

Publication counts fluctuated over the past decade with a notable spike in 2023 (65 publications) followed by a sharp decline in 2024-2025, making the trend irregular rather than steadily growing or slowing.

Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026